INNOVATE BIOPHARMA Forum: Community User: Sidewave

🚀

3Mio Volumen in den ersten 5min Nasdaq

Interessante aktie, mal sehen was so passiert die nächsten Tage

Pünktlich der 10Uhr dip....

Nachbörse war Plus

Solides Chart. Solider Anstieg. Mal Vorbörse nachher beobachten

Was meint ihr wohin geht die Reise?

To this end, Devarakonda rates NMTR shares a Buy along with a $5 price target. This figure conveys his confidence in NMTR’s ability to soar 462% in the coming year. (To watch Devarakonda’s track record, click here) Turning now to the rest of the Street, other analysts are on the same page. With 4 Buys and no Holds or Sells, the word on the Street is that NMTR is a Strong Buy. Given its $4.33 average price target, upside of 386% could be in store for investors. (See NMTR stock analysis on TipRanks)

9 Meters Biopharma (NMTR) Some biopharma companies take a broad-based approach, while others focus on a niche. 9 Meters is one of the latter, taking aim at unmet needs for gastrointestinal patients. The company’s development pipeline features drug candidates under investigation as treatments for short bowel syndrome (SBS) and celiac disease (CeD), two conditions that are both dangerous and difficult to treat. Drilling down to pipeline details, 9 Meters’ flagship product, Larazotide, is in Phase 3 development for the treatment of CeD. CeD affects about 1% of the population, yet there are no approved therapies. Top-line data from the study is expected in the second half of 2021. Furthermore, this past December, the company announced that it had entered an agreement with EBRIS, the European Biomedical Research Institute of Salerno, to investigate Larazotide as a potential treatment for respiratory complications due to COVID-19. The other major drug in the company’s pipeline is NM-002, for SBS. The company has recently announced positive Phase 1b/2a results, with a measurable impact on disease symptoms from a compound that was well-tolerated by patients. NMTR’s strong pipeline and $0.89 share price have scored it substantial praise from the pros on Wall Street. One of these NMTR bulls is Truist’s Srikripa Devarakonda. Citing Larazotide as a key component of his bullish thesis, the analyst noted, “We acknowledge investors are likely to see a pivotal trial in a tough-to-crack Celiac disease program as high risk despite encouraging Ph2b data. We model $705M/$353M in peak unadjusted/adjusted sales and see potential upside of 400% - 1650% from positive Ph3 readout.” Devarakonda also sees “significant unmet need in SBS” and continues to believe that “NM-002 has a differentiated profile vs. SOC.” His key takeaways from the recent Phase 1b/2a results include: “1) we believe that the drug showed early activity in SBS patients; all 9 patients showed meaningful reduction in total stool output volume; average TSO reduction was 42% from baseline; 2) responses occur rapidly, with effects on TSO seen within 48 hours of dosing; 3) safety profile looks favorable, we would like to see greater durability.”

🚀

Solide. Bin auf morgen gespannt. Ohne "Washington" hätten wir mehr gehalten. Meine Meinung.

Bin doch eher bei Renewi rein

Wär schon noch Luft nach oben. Meine Meinung. Bei dem Volumen.

Würdet ihr jetzt noch einsteigen zu spät?🤔 Kam eine news oder warum der hype gerade?

Und weiter gehts🚀🚀

Und weiter gehts🚀🚀